Qeen Biotechnologies has announced C$1 million in financing to expand GMP phage manufacturing, clinical trial supply and patient access across the UK and Europe.

Qeen Biotechnologies has announced that it secured C$1 million in growth financing from Investissement Québec to accelerate its expansion across the United Kingdom and Europe. The Québec biotechnology company plans to use the funding to strengthen its international presence, develop new strategic partnerships and increase access to GMP manufactured bacteriophages for clinical research and special access treatments.

The announcement reflects one of the most important changes currently taking place in phage therapy. The field is gradually moving beyond isolated academic projects and emergency compassionate treatments toward a more organised pharmaceutical model. Discovering a phage capable of infecting a pathogenic bacterium is only the first step. Before that phage can be administered to a patient, it must be sequenced, biologically characterised, purified, formulated, tested for stability and produced under conditions compatible with clinical use.

This manufacturing process is particularly demanding. Crude phage lysates contain bacterial proteins, nucleic acids, membrane fragments, culture medium residues and, when Gram negative bacteria are used for propagation, potentially high concentrations of endotoxins. These contaminants must be removed without damaging the phage particles or reducing their antibacterial potency.

Phages are also highly diverse biological entities. Differences in capsid structure, tail morphology, surface charge and sensitivity to temperature, pH or mechanical stress can affect their behaviour during filtration, chromatography, concentration and storage. A process that performs well for one phage may result in substantial losses for another. The development of stable phage cocktails therefore requires careful optimisation of each component as well as the final combined product.

Qeen intends to connect its Canadian manufacturing capabilities with hospitals, clinical trial networks, researchers, regulators, pharmaceutical companies and biotechnology partners throughout the United Kingdom and continental Europe. The company has identified GMP manufacturing, clinical trial material supply, regulatory pathways and special access programmes as central elements of this expansion.

This transatlantic strategy could help address one of the principal limitations of personalised phage therapy: fragmented infrastructure. A bacterial isolate may be obtained in one hospital, tested against phage collections in another country and ultimately supplied by a specialised manufacturing facility located elsewhere. Without coordinated procedures for susceptibility testing, quality control, regulatory documentation, transport and hospital approval, potentially useful phages may not reach patients within a clinically relevant timeframe.

Reliable phage susceptibility testing will be equally important. A visible clearing zone in a laboratory assay does not always demonstrate productive phage infection. High phage concentrations can sometimes produce lysis from without or local enzymatic effects without meaningful replication. Clinical selection should therefore combine rapid screening with more quantitative methods such as efficiency of plating, adsorption measurements, bacterial killing kinetics and resistance frequency analysis.

The investment also highlights the growing strategic importance of biomanufacturing within the phage sector. Academic laboratories remain essential for phage discovery and fundamental biology, but routine clinical deployment requires reproducible production processes, validated analytical methods, quality assurance systems and reliable supply chains.

Qeen’s stated ambition is to establish itself as an international biomanufacturing and clinical access platform for next generation phage therapeutics. The C$1 million financing gives the company additional resources to expand its operations, develop partnerships and support the movement of phage products from laboratory selection to regulated clinical use.

The long term significance of this expansion will depend on whether these collaborations can reduce manufacturing delays, harmonise quality standards and improve access for patients affected by multidrug resistant infections. In a field where the biological specificity of phages creates both therapeutic precision and logistical complexity, coordinated manufacturing infrastructure may become as important as the phages themselves.

Sources :

Qeen Biotechnologies announcement by Nancy Tawil, published on LinkedIn in July 2026.

https://qeen-bio.com/news/, https://www.investquebec.com/